Who are TAC alternate gel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Topical Benzocaine 20%, Continuous Infusion of ropivacaine 0.2%, Topical Lidocaine 4% Cream, Topical liquid lidocaine, Topical Benzocaine, Lamotrigine tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tac-alternate-gel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

TAC alternate gel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAC alternate gel (TAC alternate gel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical local anesthetic. Area: Pain management / Emergency medicine.

marketed Topical local anesthetic Voltage-gated sodium channels Pain management / Emergency medicine Small molecule Live · refreshed every 30 min

Target snapshot

TAC alternate gel (TAC alternate gel) — The University of Texas Health Science Center, Houston. TAC alternate gel is a topical anesthetic formulation combining lidocaine, prilocaine, and other agents to provide local pain relief and numbing at the site of application.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
TAC alternate gel TARGET	TAC alternate gel	The University of Texas Health Science Center, Houston	marketed	Topical local anesthetic	Voltage-gated sodium channels
Topical Benzocaine 20%	Topical Benzocaine 20%	Nourhan M.Aly	marketed	Local anesthetic	Voltage-gated sodium channels
Continuous Infusion of ropivacaine 0.2%	Continuous Infusion of ropivacaine 0.2%	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels
Topical Lidocaine 4% Cream	Topical Lidocaine 4% Cream	Children's Hospital of Philadelphia	marketed	Local anesthetic	Voltage-gated sodium channels
Topical liquid lidocaine	Topical liquid lidocaine	OHSU Knight Cancer Institute	marketed	Local anesthetic	Voltage-gated sodium channels
Topical Benzocaine	Topical Benzocaine	University of Maryland, Baltimore	marketed	Local anesthetic	Voltage-gated sodium channels
Lamotrigine tablet	Lamotrigine tablet	Dhaka Medical College	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical local anesthetic class)

American University of Beirut Medical Center · 1 drug in this class
Brown, Theodore R., M.D., MPH · 1 drug in this class
Eugene Y Rhee, MD · 1 drug in this class
IWK Health Centre · 1 drug in this class
The University of Texas Health Science Center, Houston · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TAC alternate gel — Competitive Intelligence Brief. https://druglandscape.com/ci/tac-alternate-gel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab